Pfizer’s chief executive has said that it could have 30 to 40 million doses of the vaccine before the end of the year, enough for 15 to 20 million people to get an initial shot and a booster three weeks later.
Exactly who will qualify for the initial doses has not been decided, but groups that are at higher risk for infection, or are more vulnerable to the virus, are likely to get priority. That could include health care workers as well as older adults and those who have risk factors like obesity or diabetes.
Pfizer and BioNTech say they could ramp up to 1.3 billion doses a year. That’s still far from enough to satisfy the world’s need for vaccines. If other vaccines also prove effective, companies will be able to manufacture them as well and help meet the demand.
0 Comments